{
    "medicine_id": "037f8895542d8f15047659e2f0cf05de9398e012",
    "platform_id": "DB13883",
    "metadata": {
        "name": "Antivenin micrurus Fulvius 1 g 10mL Injection powder for solution",
        "composition": "1 g 10mL Coral snake micrurus fulvius immune globulin antivenin equine",
        "clinical_particulars": {
            "therapeutic_indications": "This particular antivenin is indicated only for the treatment of envenomation caused by bites from Eastern coral snakes Micrurus fulvius fulvius and Texas coral snakes Micrurus fulvius tenere FDA Label L2176 The agent will not neutralize the venom of Arizona Sonoran coral snakes Micruroides euryxanthus or that of South American species FDA Label L2176",
            "contraindications": {
                "disease": "Patients sensitive to antivenin or horse serum may develop anaphylaxis FDA Label Therefore it is essential that prior to any antivenin administration a proper skin test be performed interpreted and therapy modified if indicated FDA Label Anaphylaxis seen with antivenins of equine origin may result in an immediate reaction shock usually occurring within 30 minutes FDA Label Signs and symptoms may develop before the needle of administration is even withdrawn from the patient and can include apprehension flushing itching urticaria edema of the face tongue and throat cough dyspnea cyanosis vomiting collapse and possibly even cardiac arrest or death FDA Label Constant attendance and observation for untoward response is mandatory whenever horse serum is administered intravenously so that should such occur injection may be discontinued and appropriate treatment instituted immediately FDA Label Even if it is appropriate for a patient to be administered the antivenin the most common adverse reactions observed after treatment with the agent has been anaphylaxis and serum sickness vomiting and abdominal pain FDA Label LD50 values are available for animal models such as the rat in which the oral LD50 is documented to be 317 mg kg and the dermal LD50 as 525 mg kg MSDS",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "North American Coral Snake Antivenin Equine is standardized for potency in mice in terms of its LD50 neutralizing capacity per milliliter as determined by intravenous injection of a graded series of mixtures of North American Coral Snake Antivenin Equine with M f fulvius venom FDA Label L2176 Based on this assay system the reconstituted contents of each vial 10 mL will neutralize about 250 mouse LD50 or approximately 2 mg of M f fulvius venom FDA Label L2176",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}